4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
2
Active Trials
200 recruiting
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
TORL Biotherapeutics, LLC is a company with 4 orphan drug designations across 3 rare diseases. Active clinical trials in 2 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| gastric cancer | Antibody-drug conjugate (ADC) consisting of a claudin 18.2 (CLDN18.2)-directed monoclonal antibody conjugated to monomethyl auristatin E (MMAE)Fully humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2) | Des.TrialAppr. |
| malignant pancreatic neoplasm | a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody against CLDN18.2a cysteine conjugated ADC, where the mc-vc-PAB-MMAE linker/payload is conjugated to mAb intermediate, an immunoglobulin G1(IgG1) molecule; | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
58
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
58
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio